This phase II trial tests how well the combination of epcoritamab and lenalidomide work in treating patients with immunodeficiency-related large B-cell lymphoma that does not respond to treatment (refractory) or that has come back after a period of improvement (relapsed). Epcoritamab is an immunotherapy that engages T-cells in the immune system to help redirect their killing effects against lymphoma cells. Lenalidomide can modulate the immune system to enhance killing effects of lymphoma by the immune system as well. Giving patients a combination of epcoritamab and lenalidomide may work better in treating refractory or relapsed immunodeficiency-related large B-cell lymphoma.
Lymphomas arising in immune deficiency which encompass monomorphic post-transplant lymphoproliferative disorder (PTLD) OR
Underlying autoimmune disease
Iatrogenic or therapy-related immunosuppression
Conditions arising from inborn errors of immunity
Patients who have received any prior therapy with a bispecific T-cell engager targeting CD3 and CD20
Patients who have received chemotherapy and/or other antineoplastic agents (except CD20- targeting monoclonal antibodies, steroids and/or radiation) within 1 week or 5 half-lives (whichever is shorter) prior to registration
Patients who have undergone autologous stem cell transplant (ASCT) within 100 days of registration
Patients who have undergone CAR-T therapy with refractoriness or relapse within 30 days of registration
Reem Karmali
Lead sponsor
Northwestern University
Sponsor institution
National Cancer Institute (NCI)
Collaborator